Fujifilm Diosynth

Executive Summary

Fujifilm Diosynth is a leading contract development and manufacturing organization (CDMO) specializing in biologics, antibodies, and drug delivery. Leveraging technical leadership in cell culture, microbial fermentation, and cell and gene therapy, the company operates world-class cGMP manufacturing facilities to support clients from pre-clinical through commercial production. As a subsidiary of Fujifilm, it benefits from strong financial backing and a global footprint, including key sites in Denmark, the US, and the UK. The company's integrated service model, combined with its emphasis on quality and innovation, positions it as a trusted partner for advancing tomorrow's medicines. With increasing demand for biologic therapeutics, Fujifilm Diosynth has been strategically expanding its capacity and capabilities. Recent investments include a large-scale cell culture facility in Hillerød, Denmark, and a new gene therapy manufacturing plant in Texas. The company's strong track record in process development and aseptic filling, coupled with its commitment to sustainability, reinforces its competitive advantage. Its ability to handle complex molecules and expedite timelines makes it a preferred CDMO for biopharmaceutical innovators globally.

Upcoming Catalysts (preview)

• Q3 2026Completion of Hillerød capacity expansion (Phase 2)90% success
• Q2 2026New long-term partnership with a top-20 pharma for commercial biologics supply70% success
• TBDFDA approval of a client's drug manufactured at Fujifilm Diosynth's Texas facility80% success